Breakthrough in HPV-Positive Throat Cancer Treatment
Human papillomavirus (HPV)-related oropharyngeal cancer has distinct biological characteristics that make it more responsive to treatment than tobacco-related cancers. Traditionally, patients endured 7 weeks of intensive chemoradiotherapy at 70 Gy doses, causing severe swallowing difficulties, permanent dry mouth, and nutritional challenges. This study investigates whether reducing radiation exposure to 60 Gy could maintain cancer control while significantly improving quality of life by minimizing side effects.
